Shares of the largest generic drug company in the world, Teva Pharmaceuticals (TEVA 0.99%), are down more than 7.5% in the last 12 months. This drop largely has to do with fears that biosimilars of the multiple sclerosis drug Copaxone, which currently accounts for a fifth of Teva's top line, may enter the market in the next couple of years. But what growth opportunities does the company have in the future, and what moves can it make to boost investor confidence? Analysts David Williamson and Max Macaluso discuss this topic in this segment from the Motley Fool's health-care show Market Checkup.
Can Teva Turn Things Around?
By Max Macaluso and Dave Williamson – Sep 17, 2013 at 10:59PM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$23B
Today's Change
(-0.99%) $0.20
Current Price
$20.03
Price as of October 30, 2025 at 4:00 PM ET
The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo